BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

877 related articles for article (PubMed ID: 19024130)

  • 1. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
    Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
    J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance.
    Trevisani F; Magini G; Santi V; Morselli-Labate AM; Cantarini MC; Di Nolfo MA; Del Poggio P; Benvegnù L; Rapaccini G; Farinati F; Zoli M; Borzio F; Giannini EG; Caturelli E; Bernardi M;
    Am J Gastroenterol; 2007 May; 102(5):1022-31. PubMed ID: 17313497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population.
    Chan SL; Mo FK; Johnson PJ; Liem GS; Chan TC; Poon MC; Ma BB; Leung TW; Lai PB; Chan AT; Mok TS; Yeo W
    J Gastroenterol Hepatol; 2011 Feb; 26(2):340-7. PubMed ID: 21261725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
    Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
    Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.
    Fattovich G; Pantalena M; Zagni I; Realdi G; Schalm SW; Christensen E;
    Am J Gastroenterol; 2002 Nov; 97(11):2886-95. PubMed ID: 12425564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems.
    Giannini E; Risso D; Botta F; Romagnoli P; Malfatti F; Fumagalli A; Testa E; Podestà E; Chiarbonello B; Polegato S; Testa R
    J Intern Med; 2004 Mar; 255(3):399-408. PubMed ID: 14871465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.
    Marrero JA; Fontana RJ; Barrat A; Askari F; Conjeevaram HS; Su GL; Lok AS
    Hepatology; 2005 Apr; 41(4):707-16. PubMed ID: 15795889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
    Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
    Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
    Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
    Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma in Lebanon: Etiology and prognostic factors associated with short-term survival.
    Yaghi C; Sharara AI; Rassam P; Moucari R; Honein K; BouJaoude J; Slim R; Noun R; Abdul-Baki H; Khalifeh M; Ramia S; Sayegh R
    World J Gastroenterol; 2006 Jun; 12(22):3575-80. PubMed ID: 16773714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
    Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
    Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].
    Petry W; Heintges T; Hensel F; Erhardt A; Wenning M; Niederau C; Häussinger D
    Z Gastroenterol; 1997 Dec; 35(12):1059-67. PubMed ID: 9487638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort.
    Zhang JF; Shu ZJ; Xie CY; Li Q; Jin XH; Gu W; Jiang FJ; Ling CQ
    PLoS One; 2014; 9(3):e88182. PubMed ID: 24609114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?
    Moya A; Berenguer M; Aguilera V; Juan FS; Nicolás D; Pastor M; López-Andujar R; Rayón M; Orbis F; Mora J; De Juan M; Carrasco D; Vila JJ; Prieto M; Berenguer J; Mir J
    Liver Transpl; 2002 Nov; 8(11):1020-7. PubMed ID: 12424715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome.
    Bucci L; Garuti F; Camelli V; Lenzi B; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Maida M; Felder M; Morisco F; Gasbarrini A; Gemini S; Foschi FG; Missale G; Masotto A; Affronti A; Bernardi M; Trevisani F; ;
    Aliment Pharmacol Ther; 2016 Feb; 43(3):385-99. PubMed ID: 26662476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of viral hepatitis on outcomes after liver resection for hepatocellular carcinoma: results from a north american center.
    Lee JJ; Kim PT; Fischer S; Fung S; Gallinger S; McGilvray I; Moulton CA; Wei AC; Greig PD; Cleary SP
    Ann Surg Oncol; 2014 Aug; 21(8):2708-16. PubMed ID: 24806113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.
    Leung TW; Tang AM; Zee B; Lau WY; Lai PB; Leung KL; Lau JT; Yu SC; Johnson PJ
    Cancer; 2002 Mar; 94(6):1760-9. PubMed ID: 11920539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.